Arvinas

Arvinas

ARVN· Manufacturing· Fiscal year ends in December

No proxy on file names the CEO of Arvinas.

Executives5

See all
  1. 1John Houston, Ph.D.FY2025
  2. 2Noah Berkowitz, M.D., Ph.D.FY2025
  3. 3Andrew SaikFY2025
  4. 4Angela Cacace, Ph.D.FY2025
  5. 5Ian Taylor, Ph.D.FY2025

Named executives and their total pay, from the Summary Compensation Table of the latest proxy.

Pay

See all

Arvinas paid its 5 named executives $17.7M in total in FY2025 (Dec).

Name
John Houston, Ph.D.Former President and Chief Executive Officer
Noah Berkowitz, M.D., Ph.D.Chief Medical OfficerNot disclosed
Andrew SaikChief Financial Officer and TreasurerNot disclosed
Angela Cacace, Ph.D.Chief Scientific OfficerNot disclosed
Ian Taylor, Ph.D.Former President of Research and Development

of each named executive, from the Summary Compensation Table of each proxy.

Peers16

See all

The FY2025 (Dec) proxy of Arvinas names 16 peer companies for pay. Among Arvinas and these peers, CEO pay was 3rd highest of 6 and total shareholder return was the lowest of 6.

3rd highest of 6in Arvinas and its pay peers, FY2025 (Dec) by CEO pay:

$4.2M$27.8M

6th highest of 6in Arvinas and its pay peers, FY2025 (Dec) by total shareholder return:

$14$414

The comes from the company's proxy. CEO pay and of each company come from its own Pay versus Performance table for the same fiscal year.

Board2

See all
  • Briggs MorrisonLead independent director · 5 yr on the boardIndependentNominating and Corporate Governance, Science and Technology—Paid as an executive
  • Everett CunninghamDirector · 1 yr on the boardIndependentAudit—Paid as an executive

The board of the latest proxy (FY2023).

Activity

  1. Pay
    Arvinas Chief Medical Officer pay fell 40% to $3.6M. The stock fell 38% in FY2025 (Dec).
    DEF 14A
  2. Pay
    Arvinas President pay fell 49% to $6.5M. The stock fell 38% in FY2025 (Dec).
    DEF 14A
  3. Pay
    Arvinas Former President of Research and Development pay fell 79% to $903.4K. The stock fell 38% in FY2025 (Dec).
    DEF 14A
  4. Pay
    Arvinas Chief Scientific Officer pay rose 11% to $3.3M. The stock fell 38% in FY2025 (Dec).
    DEF 14A
  5. Pay
    Arvinas Former CFO pay fell 96% to $105.9K. The stock fell 53% in FY2024 (Dec).
    DEF 14A
  6. Pay
    Arvinas Former CFO pay fell 17% to $3.5M. The stock fell 58% in FY2022 (Dec).
    DEF 14A
  7. Pay
    Arvinas President pay rose 67% to $12.7M. The stock fell 53% in FY2024 (Dec).
    DEF 14A
  8. Pay
    Arvinas President pay fell 24% to $9.5M. The stock fell 58% in FY2022 (Dec).
    DEF 14A
  9. Pay
    Arvinas Former President of Research and Development pay rose 54% to $4.2M. The stock fell 53% in FY2024 (Dec).
    DEF 14A
  10. Pay
    Arvinas Former President of Research and Development pay fell 17% to $3.5M. The stock fell 58% in FY2022 (Dec).
    DEF 14A
  11. Pay
    Arvinas Former CFO pay fell 22% to $2.7M. The stock rose 20% in FY2023 (Dec).
    DEF 14A
  12. Pay
    Arvinas Former Chief Medical Officer pay fell 22% to $2.7M. The stock rose 20% in FY2023 (Dec).
    DEF 14A
  13. Pay
    Arvinas Former Chief Medical Officer pay fell 18% to $3.5M. The stock fell 58% in FY2022 (Dec).
    DEF 14A
  14. Pay
    Arvinas President pay fell 20% to $7.6M. The stock rose 20% in FY2023 (Dec).
    DEF 14A
  15. Pay
    Arvinas Former President of Research and Development pay fell 22% to $2.7M. The stock rose 20% in FY2023 (Dec).
    DEF 14A

Filings6

See all
Proxy statementDEF 14AApr 29, 2026FY2025
Annual report10-KFeb 24, 2026FY2025
Proxy statementDEF 14AApr 29, 2025FY2024
Annual report10-KFeb 11, 2025FY2024
Proxy statementDEF 14AApr 16, 2024FY2023
Annual report10-KFeb 27, 2024FY2023
For the press:Download CSVDownload PNGHow to use our data